The Pink Sheet’s regularly updated list of products containing new active substances that have been approved for marketing in the EU under the centralized authorization procedure now includes seven new products – Nuvaxovid (COVID-19 Vaccine (recombinant, adjuvanted)), Xevudy (sotrovimab), Aspaveli (pegcetacoplan), Vaxneuvance (Pneumococcal polysaccharide conjugate vaccine (15‑valent, adsorbed)), Cibinqo (abrocitinib), Rybrevant (amivantamab) and Artesunate Amivas (artesunate).
The list, which contains information dating back to January 2018, comprises brand name, generic name, company, therapeutic indication, date of...







